Human TRAIL R2/TNFRSF10B Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB631
Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Conjugate
Catalog #
Key Product Details
Validated by
Biological Validation
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
Agonist Activity
Cited:
Immunohistochemistry-Paraffin, Neutralization, Flow Cytometry, Bioassay, Functional Assay
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # 71903
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant human TRAIL R2/TNFRSF10B
Met1-Glu182
Accession # CAG46696
Met1-Glu182
Accession # CAG46696
Specificity
Detects human TRAIL R2/TNFRSF10B in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R3, rhTRAIL R4, or rhDcR3.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human TRAIL R2/TNFRSF10B Antibody
Human TRAIL R2/TNFRSF10B Antibody Induces Apoptosis of Jurkat Cells.
Human TRAIL R2/TNFRSF10B Monoclonal Antibody induces apoptosis of the Jurkat human acute T cell leukemia cell line in a dose-dependent manner, as measured by Resazurin (Catalog # AR002) . The ED50 for this effect is typically 2-12 ng/mL.
Detection of Human TRAILR2/TNFRSF10B by Western Blot
Cleavage of FRET probe is indicative of caspase activation.Cells were treated with (A) 0–300 ng/ml TRAIL for 2.5 hours or (B) 0–50 µg/ml anti-DR5 antibody for 20 h. The resultant cells were analyzed by western blotting using antibodies specific to caspase 3 (C3), caspase 8 (C8), and CFP/YFP. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0107010), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human TRAILR2/TNFRSF10B by Functional
MB231_CFP-YFP cells retain sensitivity to TRAIL and anti-DR5 antibody.(A) Parental MB231 (filled black) and MB231_CFP-YFP (open clear) cells were treated with TRAIL (0–100 ng/ml) for 2.5 h or anti-DR5 antibody (0–200 µg/ml) for 20 h, at the indicated concentrations. Cell viability was determined by MTT assay. (B) Cells were treated as in A and analyzed for apoptosis by flow cytometry after staining with Annexin-V-APC and propidium iodide (PI). p-values were determined using a Student’s t-test. EC50 values were determined using nonlinear curve fitting as described in the Materials and Methods section. For each EC50 value, 95% confidence intervals reflecting the statistical accuracy are reported in Table 1. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0107010), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human TRAIL R2/TNFRSF10B Antibody
Application
Recommended Usage
Agonist Activity
2-12 ng/mL
Sample: Jurkat human acute T cell leukemia cell line
Sample: Jurkat human acute T cell leukemia cell line
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TRAIL R2/TNFRSF10B
Human TRAIL R2, also called DR5 and TRICK 2 is a type 1, TNF R family, membrane protein which is a receptor for TRAIL (APO2 ligand). In the new TNF superfamily nomenclature, TRAIL R2 is referred to as TNFRSF10B. TRAIL R2 cDNA encodes a 440 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among TNF receptor family proteins, TRAIL R2 is most closely related to TRAIL R1/DR4, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R2 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R2/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R2, an additional TRAIL R1/DR4, which tranduces apoptosis signaling, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.
References
- Chaudhary, P.M. et al. (1997) Immunity 7:821.
- Walczak, H. et al. (1997) EMBO J. 16:5386.
- Golstein, P. (1997) Curr. Biol. 7:R750.
Long Name
TRAIL Receptor 2
Alternate Names
CD262, DR5, TNFRSF10B, TRAILR2
Gene Symbol
TNFRSF10B
UniProt
Additional TRAIL R2/TNFRSF10B Products
Product Documents for Human TRAIL R2/TNFRSF10B Antibody
Product Specific Notices for Human TRAIL R2/TNFRSF10B Antibody
For research use only
Loading...
Loading...
Loading...
Loading...